The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Romain Banchereau
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
 
Habib Rahman Hamidi
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Ning Leng
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
 
Will Harris
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Peter H. O'Donnell
Honoraria - Astellas Pharma; Atheneum; Dedham Group; FirstWord; Genentech/Roche; Health Advances; Janssen; Merck; OncLive; Schlesinger Associates; Seagen
Consulting or Advisory Role - Merck
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Janssen; Janssen; Merck; Seattle Genetics/Astellas
Other Relationship - Janssen; Nektar; NIH
 
Edward Ernest Kadel
Employment - Genentech/Roche
Stock and Other Ownership Interests - Celgene; Clinuvel; Compugen; Epizyme; Genentech/Roche; Gilead Sciences; Gilead Sciences (I); Mannkind; Merck; Vertex
Travel, Accommodations, Expenses - Genentech/Roche
 
Kobe Chi Yung Yuen
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
 
Dexter Jin
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Hartmut Koeppen
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
 
Darren Tayama
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
 
Enrique Grande
Honoraria - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Eisai; Eusa Pharma; Genzyme; IPSEN; Janssen-Cilag; Lexicon; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche; Roche
Research Funding - AstraZeneca (Inst); Ipsen (Inst); Molecular Templates (Inst); Pfizer (Inst); Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Roche/Genentech
 
Jose Arranz
Honoraria - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Janssen-Cilag; MSD Oncology; Novartis
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Janssen-Cilag; MSD Oncology; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Pfizer
 
Maria De Santis
Honoraria - Astellas Pharma; Bayer; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Basilea; Bayer; BioClin Therapeutics; BioSyn Healthy Pharma; Bristol-Myers Squibb; Ferring; GlaxoSmithKline; Ipsen; Janssen; Merck Sharp & Dohme; Pierre Fabre; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen; Synthon; Takeda
Research Funding - Pierre Fabre
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Roche; Sanofi
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Eiji Kikuchi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; MSD; Ono Pharmaceutical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Janssen; Kyorin; MC Medical; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Kissei Pharmaceutical (Inst); Kyorin (Inst); Kyorin (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst)
 
Xiaodong Shen
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
 
Aristotelis Bamias
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Debiopharm Group; MSD; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Pfizer; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; Pfizer; Roche
 
Sanjeev Mariathasan
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Patent describing Atezolizumab invention :